利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

193 条记录 (耗时 0.029 秒)

    METHODS AND KITS FOR THE DETECTION OF SARS-COV-2
    3.
    发明申请
    METHODS AND KITS FOR THE DETECTION OF SARS-COV-2 有权

    公开(公告)号：US20230043710A1

    公开(公告)日：2023-02-09

    申请号：US17931893

    申请日：2022-09-13

    申请人： THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

    发明人： David Engelthaler ,  Jolene Bowers ,  James Schupp

    IPC分类号： C12Q1/6874 ,  C12Q1/686 ,  C12Q1/682

    摘要： Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 40 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5′ terminus is labeled with a fluorophore and the 3′ terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

    SYSTEMS, METHODS, AND DEVICES FOR ROTATING INSULIN ADMINISTRATION SITES
    6.
    发明申请
    SYSTEMS, METHODS, AND DEVICES FOR ROTATING INSULIN ADMINISTRATION SITES 有权

    公开(公告)号：US20210298650A1

    公开(公告)日：2021-09-30

    申请号：US17217711

    申请日：2021-03-30

    申请人： The Translational Genomics Research Institute

    发明人： John Blanchard ,  Sampathkumar Rangasamy

    IPC分类号： A61B5/145 ,  A61B5/00 ,  A61M5/142 ,  G16H20/17

    摘要： An application running on a device to manage insulin site rotation may read a configuration file including a group, a plurality of sites in the group, and an image associated with the group. The application may detect an input selecting a site from the plurality of sites for administration of an insulin management device. The application may also set the selected site as unavailable for a predetermined duration in response to the input selecting the site. A log entry may be written to track usage of the site in response to the input selecting the site. A visual indicator on the selected site may show that the site is recently selected in response to detecting the input selecting the site within a predetermined duration. The insulin management device may be a pump, a syringe, or a glucose monitor.